摘要
内分泌治疗是目前术后乳腺癌及晚期转移性乳腺癌的重要治疗手段.然而雌激素受体(ER)阳性乳腺癌患者一旦发生内分泌耐药,其生存期明显缩短.影响内分泌耐药的机制复杂,一些ER通路中某种成分的失调、生长因子信号通路相关分子的信号传导及ER转录因子的共调节剂、乳腺癌肿瘤微环境、上皮间质转化(EMT)及相关microRNAs(miRNA)等都是导致乳腺癌内分泌耐药的重要因素.在这些影响因素中,生长因子通路表达的增加,特别是EGFR/HER2通路与内分泌治疗耐药的关系是近来研究的热点.阻断ER及生长因子受体信号通路间串话,减少逃离通路的新治疗手段被证实在临床前模型中有较高的有效性.
Endocrine therapy is one of the most important therapies for treating breast cancer after surgery and metastatic breast cancer. However,once the patients with ER positive of breast cancer begin to resist on the endocrine therapy,the survival period will shorten greatly. The mechanisms of endocrine resistance are complicated,including many factors,such as desregulation of estrogen receptors, transduction of EGFR signaling pathway,coregulators of ER transcriptors, microenvironment of breast tumor,EMT and miRNAs. Among all of these factors,transduction of EGFR/HER2 signaling pathway has become a hotspot recently. Therefore,it will become an effective preclinical model to treat the drug resistance by blocking the crosstalk between ER and EGFR signaling pathway and reducing escape pathway.
出处
《转化医学电子杂志》
2017年第9期62-65,69,共5页
E-Journal of Translational Medicine
基金
辽宁省博士启动项目基金(201702221)
关键词
乳腺癌
内分泌
耐药
雌激素受体
breast cancer
endocrine therapy
drug resistance
estrogen receptor
